HJ SCIENCE-B

Hua Jian Future-B opened higher but reversed lower in the morning session, closing at HK$42.80, down 3.82% from the previous close of HK$44.50, mainly due to profit-taking after a recent sharp rally. The stock initially surged to an intraday high of HK$47.16 (up ~6%) before pulling back to a low of HK$41.94, creating a range of 12.3%. Listed only about three weeks ago, the stock is now 47.8% below its 52-week high of HK$82.00, yet still 39.05% above the 52-week low of HK$30.78, with a YTD gain of 21.38%. Today's closing price of HK$42.80 remains about 12.8% above the 20-day moving average (HK$37.931), suggesting elevated short-term valuation prompted profit-taking. However, with trading volume shrinking to 90,700 shares, the pullback is relatively muted compared to prior days when intraday gains exceeded 20%, indicating persistent active-fund-driven volatility.

Hua Jian Wei Lai surged in its debut morning session, climbing from HK$33.76 to HK$35.50, a 5.15% gain, as the market positively priced its innovative pipeline targeting autoimmune, metabolic, and oncology diseases. The stock formed a bottoming-out pattern, hitting an intraday low of HK$33.30 before rebounding to the day's high of HK$35.50, with a thin volume of only 2,200 shares. The company remains loss-making, with a P/E of -17.47x, P/B of 7.02x, and a market cap of approximately HK$2.61 billion. While the stock has risen about 5.2% from its opening price, the sustainability of buying interest remains unclear.

Hua Jian Future-B opened lower and recovered somewhat intraday, touching a low of 33.0 HKD before closing at 33.02 HKD, down 5.87%, driven by persistent negative sentiment following its debut. The stock has repeatedly suffered single-day drops of over 5% recently, and today's price action confirms the bearish trend. At 59.73% below the 52-week high of 82 HKD and below the MA20 of 37.061 HKD, the price remains under pressure, though the PE of -16.24x and PB of 6.53x highlight valuation challenges.

Hua Jian Future (Chengdu) Technology Co., Ltd. staged a morning session reversal, opening at HK$32.0 and plunging to the intraday low before rebounding to close 5.06% higher at HK$35.3, likely driven by renewed optimism over its autoimmune and metabolic pipeline progress. The stock remains 56.95% below its 52-week high of HK$82 and 14.68% above the 52-week low of HK$30.78, with a YTD gain of 0.11%, yet trades below the 20-day MA of HK$37.389, indicating weak near-term momentum. With a market cap of ~HK$2.6 billion, a PB of 6.98x, and a negative PE of -17.37x reflecting ongoing losses, the company's focus on reverse-innovation R&D strategy awaits clinical catalysts.

6132.HK opened lower and trended lower during the morning session, with the opening price of HKD 33.600 becoming the intraday high before sliding to a close of HKD 32.100, marking a 5.03% decline on a thin volume of 4,800 shares and a turnover of HKD 160,010. The stock has fallen below both its 20-day moving average (HKD 37.438) and 60-day moving average (HKD 37.438), and remains 60.85% below its 52-week high of HKD 82.000 (June 22, 2026), with a year-to-date decline of 8.96%. The company's price-to-book ratio stands at 6.35x, while its negative price-to-earnings ratio of -15.8x reflects ongoing earnings pressure. That said, the stock has edged up 4.29% from its 52-week low of HKD 30.78 set on July 7, suggesting some near-term support.